Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4167586 in Participants With Obesity or Overweight
NCT07225556Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised trial of LY4167586 in obesity (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number and Incidence of Serious Adverse Events at 29 weeks. Started Nov 2025; status: active, not recruiting.
02
Drugs
LY4167586
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07225556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225556.